Heavy menstrual bleeding, pelvic pressure, and infertility are the main clinical manifestations linked to uterine fibroids. Hormonal contraceptives, including coformulated estrogen and progestin oral contraceptives, progestin-only birth control pills, and long-lasting levonorgestrel-releasing intrauterine system, have long been used to manage heavy menstrual bleeding (menorrhagia), but they do not reduce fibroid tumor volume or resolve bulk symptoms. During the forecast period, launches of novel selective progesterone receptor regulators (SPRMs) and gonadotropin-releasing hormone (Gn-RH) antagonists will provide more efficacious medical alternatives over procedures such as hysterectomy and myomectomy in the long-term management of uterine fibroids.
Primary research: Six country-specific interviews with uterine fibroids specialists (gynecologists, one radiologist, and one gynecological pathologist).
Epidemiology: Total prevalent cases of uterine fibroids by country, diagnosed and drug-treated cases.
Emerging therapies: Phase III/PR: 4; Phase II: 3; coverage of select preclinical and Phase I products.
Market forecast: Drug-level sales and patient share of key uterine fibroids therapies in 2026. Sales and patient share of ulipristal in the EU5 in 2016.
Drugs: ulipristal, telapristone, vilaprisan, elagolix, relugolix, OBE-2109, leuprolide